Open AccessPB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE‐BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R‐CHOP VS R‐CHOP ALONE FOR NEWLY DIAGNOSED HIGH‐INTERMEDIATE AND HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA
Author(s) -
Vitolo U.,
Nowakowski G. S.,
Burke J. M.,
Fox C. P.,
Trneny M.,
Chiappella A.,
WaldronLynch M.,
Hadar N.,
Pachori A.,
Lenz G.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000851284.83380.89
Subject(s) - medicine , lenalidomide , vincristine , diffuse large b cell lymphoma , oncology , chop , international prognostic index , regimen , lymphoma , chemotherapy , multiple myeloma , cyclophosphamide